CFO
ALNY icon

Callan Family Office’s Alnylam Pharmaceuticals ALNY Stock Holding History

Callan Family Office’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$927K Buy
3,078
+43
+1% +$13K 0.02% 616
2026
Q1 		$1M Sell
3,035
-579
-16% -$197K 0.02% 556
2025
Q4 		$1.44M Buy
3,614
+858
+31% +$380K 0.03% 439
2025
Q3 		$1.26M Sell
2,756
-175
-6% -$71.3K 0.04% 340
2025
Q2 		$956K Buy
2,931
+1,913
+188% +$529K 0.03% 416
2025
Q1 		$275K Sell
1,018
-24
-2% -$6.17K 0.02% 443
2024
Q4 		$245K Buy
+1,042
New +$274K 0.02% 549

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Callan Family Office's ALNY Position: Q2 2026 in Review

Callan Family Office increased its Alnylam Pharmaceuticals (ALNY) stake by 1.4% in Q2 2026, buying an estimated $13K and bringing the position to 3,078 shares worth $927K. The position accounts for 0.02% of the portfolio, ranked #616.

Callan Family Office first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.44M in Q4 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Callan Family Office held 3,078 shares of Alnylam Pharmaceuticals worth $927K as of Q2 2026.
  • Callan Family Office bought 43 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $13K.
  • Alnylam Pharmaceuticals made up 0.02% of Callan Family Office's portfolio in Q2 2026, its #616 holding.
  • Callan Family Office first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Callan Family Office's Alnylam Pharmaceuticals position peaked at $1.44M in Q4 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.